Original Article
Etanercept as Monotherapy in Patients with Psoriasis
N Engl J Med 2003; 349:2014-2022November 20, 2003
- Abstract
Background
Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the treatment of plaque psoriasis.
Methods
In this 24-week, double-blind study, 672 patients underwent randomization and 652 either received placebo or received etanercept subcutaneously at a low dose (25 mg once weekly), a medium dose (25 mg twice weekly), or a high dose (50 mg twice weekly). After 12 weeks, patients in the placebo group began twice-weekly treatment with 25 mg of etanercept. The primary measure of clinical response was the psoriasis area-and-severity index.
Results
At week 12, there was an improvement from base line of 75 percent or more in the psoriasis area-and-severity index in 4 percent of the patients in the placebo group, as compared with 14 percent of those in the low-dose–etanercept group, 34 percent in the medium-dose–etanercept group, and 49 percent in the high-dose–etanercept group (P<0.001 for all three comparisons with the placebo group). The clinical responses continued to improve with longer treatment. At week 24, there was at least a 75 percent improvement in the psoriasis area-and-severity index in 25 percent of the patients in the low-dose group, 44 percent of those in the medium-dose group, and 59 percent in the high-dose group. The responses as measured by improvements in the psoriasis area-and-severity index were paralleled by improvements in global assessments by physicians and the patients and in quality-of-life measures. Etanercept was generally well tolerated.
Conclusions
The treatment of psoriasis with etanercept led to a significant reduction in the severity of disease over a period of 24 weeks.
Media in This Article
Figure 1
Clinical Response to Etanercept Treatment as Measured by the Psoriasis Area-and-Severity Index (Panel A), the Physician's Static Global Assessment (Panel B), and the Patient-Reported Dermatology Life Quality Index (Panel C).Table 1
Base-Line Demographic and Clinical Characteristics of the Patients.Article Activity
- Article
Psoriasis is a chronic inflammatory skin disorder that affects approximately 2 percent of the world's population.1 Patients report substantial disease-related inability to work2 and may face discrimination, financial distress, or depression.3 Rapp et al.4 showed that psoriasis causes more physical and mental disability than many major diseases. Current therapies for psoriasis are not satisfactory.3 Many therapies are associated with cumulative toxicity that may limit their usefulness in this chronic disease.1-4
Psoriasis is characterized by the infiltration of the skin by activated T cells and an abnormal proliferation of keratinocytes. As a result of overproduction by T cells, keratinocytes, dendritic cells, and Langerhan's cells, the concentrations of the inflammatory cytokine tumor necrosis factor (TNF) are higher in psoriatic lesions than in uninvolved skin in patients with psoriasis or in normal persons.5-8 Serum and lesional TNF concentrations decrease after the effective treatment of psoriasis, and these decreases correlate with clinical improvement, suggesting that TNF has an important role in the disease.9 Recognition of the contributions of T cells and inflammatory cytokines to the pathogenesis of psoriasis has led to the development of new biologic treatment strategies.
Etanercept is a recombinant human TNF-receptor fusion protein that antagonizes the effects of endogenous TNF by competitively inhibiting its interaction with cell-surface receptors. Etanercept has been shown to be effective in patients with rheumatoid arthritis10,11 and in patients with psoriatic arthritis, in whom etanercept also improved psoriatic skin lesions.12,13 On the basis of these results, we conducted a study to evaluate the safety and efficacy of three different regimens of etanercept in patients with moderate-to-severe psoriasis.
Methods
Study Patients
The institutional review boards of the participating medical centers approved the protocol, and all patients gave written informed consent before any study-related procedures were performed. Patients were eligible if they were at least 18 years of age, had active but clinically stable plaque psoriasis involving at least 10 percent of the body-surface area, had a minimal psoriasis area-and-severity index14 of 10 (indicating moderate-to-severe psoriasis) during the screening period, and had previously received phototherapy or systemic psoriasis therapy at least once or had been a candidate for such therapy. Patients with guttate, erythrodermic, or pustular psoriasis at the time of screening were excluded, as were those with other active skin conditions that would interfere with evaluations. Patients were also excluded if they had previously received etanercept or antibody to TNF; if they had received anti-CD4 antibodies or interleukin-2–diphtheria-toxin fusion protein within the previous six months; if they had received any biologic or investigational drug, psoralen–ultraviolet A phototherapy, systemic corticosteroids, or systemic psoriasis therapy within the previous four weeks; if they had received ultraviolet B phototherapy, topical corticosteroids, vitamin A or D analogues, or anthralin within the previous two weeks; or if they had taken antibiotics within the previous week. Patients were permitted to use stable doses of topical corticosteroids on the scalp, axilla, and groin during the study if these preparations were of low or moderate potency.
Study Drug
Etanercept (Enbrel, Immunex–Wyeth) was supplied to patients in syringes, each containing the contents of one reconstituted vial of etanercept or matching placebo. All study drug was administered by the patient by subcutaneous injection.
Study Design
This was a placebo-controlled, double-blind, parallel-group, phase 3 study that evaluated etanercept as a treatment for psoriasis in patients at 47 sites in the United States. Eligible patients were randomly assigned to receive placebo or etanercept for 24 weeks. During the first 12 weeks of the double-blind treatment period, patients received etanercept at a low dose (25 mg once weekly), a medium dose (25 mg twice weekly), or a high dose (50 mg twice weekly) or placebo. In order to maintain masking with respect to the treatment assignments, all patients received two injections per dose of study drug, with placebo making up the balance of injections for patients assigned to the low-dose–etanercept regimen or the medium-dose–etanercept regimen. After 12 weeks of treatment, patients in the placebo group began double-blind treatment with etanercept (at the medium dose, 25 mg twice weekly). Safety and efficacy were evaluated at weeks 2, 4, 8, 12, 16, 20, and 24. The first patient underwent randomization in December 2001, and the last patient in April 2002; the week 24 observation was made in the last patient in October 2002. Patients underwent central randomization with the use of a permuted-block randomization list, with equal allocation to each of the four treatment groups.
The study was designed by Immunex, Dr. Gottlieb, and other members of the Etanercept Psoriasis Study Group. Data were collected by the investigators in the study group (the complete data set was held at the central data-processing facility at Amgen) and were analyzed by Dr. Zitnik and Ms. Wang. The academic investigators had full access to the data. The lead investigators wrote the paper with editorial assistance from Amgen and Immunex, and the investigators made the decisions about publication in collaboration with Amgen.
Efficacy End Points
The primary measure of efficacy was the proportion of patients in each treatment group in whom there was an improvement of at least 75 percent from base line in the psoriasis area-and-severity index at week 12. The index was calculated according to the standard method outlined by Fredriksson and Pettersson.14 The psoriatic lesions are scored on a scale of 0 to 4 for three characteristics: erythema, induration, and desquamation. The lesions are scored within four anatomical regions: head, trunk, arms, and legs. Within each of these regions, the area of involvement is scored on a scale of 0 to 6. Each region's contribution to the overall body-surface area is corrected for by a separate coefficient. The corrected scores for each region are summed to provide the overall index. The index ranges from 0 (no psoriasis) to 72 (severe disease). The proportions of patients with an improvement in the index of at least 50 percent and the proportions with an improvement of at least 90 percent were also determined. The Physician's Static Global Assessment of Psoriasis was reported on a scale of 0 to 5, with 0 indicating no psoriasis (clear of disease) and higher scores indicating more severe disease. Two patient-reported outcomes were assessed: the Dermatology Life Quality Index, calculated from a summary of 10 items on a patient questionnaire in which all the items were weighted equally, which has been validated for use in patients with psoriasis,15 and the Patient's Global Assessment of Psoriasis (on a scale ranging from 0 [good] to 5 [severe]).
Safety End Points
All patients who underwent randomization and received at least one dose of study drug were included in the safety analysis, including analysis of adverse events, infections, and premature withdrawal from the study. Standard laboratory tests, including hematologic analysis, analysis of serum chemistry, and urinalysis profiles were performed at screening, at base line, and at weeks 12 and 24. Adverse events and abnormal laboratory values were graded on a scale derived from the Common Toxicity Criteria of the National Cancer Institute. Serum samples obtained at base line and week 24 were tested for antibody to etanercept with the use of an enzyme-linked immunosorbent assay (ELISA).16 Samples that were positive on ELISA were tested for neutralizing antibodies with the use of a binding assay.
Statistical Analysis
All patients who received at least one dose of double-blind study treatment were included in the analyses. All statistical tests were two-sided with a significance (α) level of 0.05. Comparisons between treatment groups were made with the use of Pearson's chi-square test or Fisher's exact test for binary end points, the Mantel–Haenszel row mean score test for ordinal end points, and nonparametric tests (such as the Wilcoxon rank-sum test) for continuous end points. The last observations were carried forward in cases of missing data or early termination.
The primary efficacy analysis compared each of the three etanercept groups with the placebo group in terms of the proportion of patients with an improvement of at least 75 percent in the psoriasis area-and-severity index at week 12. Comparisons were made with the use of Pearson's chi-square test. Hochberg's step-up procedure for multiple comparisons was used to maintain the significance level at 0.05 for the three comparisons. Statistical comparisons at time points other than 12 weeks were not corrected for multiple comparisons.
The primary analysis was performed after all patients completed the week 12 assessments. All patients and study-site personnel, however, remained unaware of the results and the treatment-group assignments. Additional analyses of the data from the 24 weeks of double-blind treatment were performed after all patients completed the week 24 assessment.
The sample size was chosen both to test the efficacy of etanercept and to expose an adequate number of patients to treatment for the assessment of safety. The sample size was estimated for the primary efficacy measurement. On the basis of the results observed in a phase 2 study, this study had more than 99 percent power to detect a difference of 25 percent in the proportion of patients with an improvement of at least 75 percent in the psoriasis area-and-severity index between an etanercept group and the placebo group. The primary analysis was performed after week 12, and no interim analyses were performed.
Results
Study Patients
A total of 672 patients underwent randomization, and 652 patients received at least one dose of double-blind study treatment. Twenty patients were randomly assigned to a treatment group but did not receive any study drug (two patients in the placebo group, nine in the low-dose–etanercept group, five in the medium-dose–etanercept group, and four in the high-dose–etanercept group). The primary analyses of efficacy and safety are based on the 652 patients who received at least one dose. The groups were balanced in terms of demographic characteristics, disease history, and the severity of disease at base line (Table 1Table 1
Base-Line Demographic and Clinical Characteristics of the Patients.). The population of patients in this study was predominantly male (67 percent) and white (87 percent), and the mean age was 45.1 years. The mean duration of psoriasis was 18.7 years, and 22 percent of the patients had psoriatic arthritis. Eighty-eight percent of patients had previously received topical corticosteroids, and 76 percent had previously received systemic therapy or phototherapy for psoriasis. The mean affected body-surface area was 28.7 percent, and the mean base-line psoriasis area-and-severity index was 18.4. Overall, 94 percent of the patients completed 12 weeks of treatment and 88 percent completed 24 weeks, with similar proportions of patients completing treatment in each group.Efficacy
The primary efficacy end point for this study was the proportion of patients with an improvement of at least 75 percent in the psoriasis area-and-severity index at week 12 (Table 2Table 2
Clinical Responses at Week 12 and Week 24.). At week 12, there was such an improvement in 4 percent of the patients in the placebo group, as compared with 14 percent in the low-dose–etanercept group, 34 percent in the medium-dose–etanercept group, and 49 percent in the high-dose–etanercept group (P<0.001 for all three comparisons with the placebo group). There was a statistically significant difference from the placebo group in the proportion of patients with such an improvement as early as week 4 in the high-dose group and week 8 in the medium-dose group.The proportion of patients with an improvement in the psoriasis area-and-severity index of at least 50 percent in all three etanercept groups and the proportion with an improvement of at least 90 percent in the medium-dose and high-dose groups were also significantly different from the proportions in the placebo group at week 12 (Table 2). The mean percentage improvements in the psoriasis area-and-severity index from base line were statistically significant for all three etanercept groups as early as week 2 of the study; by week 12, the mean level of improvement was 40.9 percent in the low-dose group, 52.6 percent in the medium-dose group, and 64.2 percent in the high-dose group, as compared with 14.0 percent in the placebo group (Table 2 and Figure 1Figure 1
Clinical Response to Etanercept Treatment as Measured by the Psoriasis Area-and-Severity Index (Panel A), the Physician's Static Global Assessment (Panel B), and the Patient-Reported Dermatology Life Quality Index (Panel C).).Results of the week 24 evaluations are also presented in Table 2. At week 24, an improvement of 75 percent or more had been achieved in 25 percent of the patients in the low-dose–etanercept group, 44 percent of those in the medium-dose group, and 59 percent of those in the high-dose group. Because the patients in the placebo group received etanercept after week 12, this analysis did not include a placebo control. At week 24, an improvement of 75 percent or more had been achieved in 33 percent of the patients in the original placebo group who had begun receiving etanercept after week 12 — a response rate that is consistent with that in the medium-dose–etanercept group at week 12 (34 percent) (Table 2).
At week 12, the proportion of patients in each of the etanercept groups who were assessed by the physician as being clear or almost clear of psoriasis was significantly different from that in the placebo group (P<0.001 for all three comparisons) (Table 2). These differences were significant for all the etanercept groups as early as week 4 of the study. In addition, at week 2, the Physician's Static Global Assessment in all the etanercept groups was significantly different from that in the placebo group.
The mean percentage improvement from base line in the Dermatology Life Quality Index was significant in all the etanercept groups at week 2; by week 12, the mean improvement was 47.2 percent in the low-dose group, 50.8 percent in the medium-dose group, and 61.0 percent in the high-dose group, as compared with 10.9 percent in the placebo group (P<0.001 for all three comparisons with the placebo group) (Figure 1). Scores on the Patient's Global Assessment in all three etanercept groups were also significantly different from those in the placebo group at week 12 (P<0.001 for all comparisons) (Table 2). As early as week 2, the global assessments by the patients in all the etanercept groups were significantly different from those in the placebo group.
Safety
Etanercept was well tolerated in this population of patients, with adverse events and infections occurring in similar proportions of patients in each group during the study (Table 3Table 3
Adverse Events Occurring in at Least 5 Percent of Patients in Any Treatment Group.). Most events were of mild or moderate intensity. During the 24-week study, 27 patients withdrew because of adverse events, and 16 withdrew because of lack of efficacy. No cases of tuberculosis or opportunistic infections were reported during the study.All laboratory abnormalities were of mild or moderate intensity, and no patient withdrew because of an abnormal laboratory result. Eight etanercept-treated patients had serum samples that tested positive for non-neutralizing anti-etanercept antibodies, as determined by ELISA and a binding assay. We did not observe differences in efficacy or adverse-event profiles between these eight patients and the patients without anti-etanercept antibodies, but the small number provided limited statistical power.
Discussion
Our large, multicenter trial demonstrates the efficacy and tolerability of etanercept, a TNF antagonist, in the treatment of psoriasis. The study underscores the critical role of TNF in the pathogenesis of this debilitating disease.
In this study, etanercept was effective in patients with psoriasis. Significant, dose-dependent increases were observed at the 12-week assessment in the proportions of patients in whom an improvement of at least 75 percent in the psoriasis area-and-severity index was achieved, and improvement continued with continued etanercept therapy. The mean percentage improvements from base line in the response as measured by this index were statistically significant in the three etanercept groups as early as week 2.
Etanercept induced a marked clearance of psoriatic skin lesions. A significantly greater proportion of etanercept-treated patients than patients in the placebo group had a “clear” or “almost clear” status at the 12-week assessment, and the responses continued to improve in a dose-dependent manner through 24 weeks of treatment.
The evaluation of the treatment effect in psoriasis solely with the use of physician-reported end points that rely mainly on the body-surface area involved may be suboptimal. The patient's perspective on the improvement of skin disease and the quality of life should also be considered.17 In addition, rapid clearing of skin lesions is an important aspect of effective psoriasis management and may correlate with the patient's satisfaction with treatment.3 After two weeks of treatment, etanercept produced statistically significant and clinically meaningful improvements in patients' global assessments of disease and in the quality of life as assessed by the Dermatology Life Quality Index.
Etanercept was well tolerated in this study. The proportions of patients with adverse events and infections were similar in all active-treatment groups and the placebo group at week 12. We could not compare the etanercept groups with the placebo group with respect to safety at week 24 because of the crossover of patients from placebo to active drug at week 12. The pattern of infections and adverse events, however, did not change through 24 weeks of therapy. The dose of 50 mg of etanercept administered twice weekly that was used in the high-dose group in this study was higher than that used in previous studies of rheumatoid arthritis and psoriatic arthritis.10,13 In this study, the safety profile was similar to that observed in the group receiving 25 mg of etanercept twice weekly. Given the apparent increase in efficacy achieved with the higher dose, the risk–benefit ratio is favorable.
Our results are interesting in the light of increasing clinical evidence that the disruption of specific immune interactions can improve psoriasis. Other agents being evaluated for the treatment of psoriasis include another TNF antagonist, infliximab,18,19 an anti-CD11a monoclonal antibody, efalizumab,20 and a soluble LFA-3–IgG fusion protein, alefacept.21 The efficacy results of our study underscore the importance of TNF and its inhibition in psoriasis.
TNF and interferon-γ are produced by type 1 helper T cells (Th1) found in psoriatic plaques.22 TNF induces the expression of adhesion molecules such as intercellular adhesion molecule 1 and vascular-cell adhesion molecule on keratinocytes and vascular endothelial cells and induces the production of chemokines including interleukin-8. The production of adhesion molecules and chemokines results in the recruitment of additional inflammatory cells to the plaque. The recruited cells can then produce further TNF and interferon-γ, potentially amplifying local inflammation and keratinocyte proliferation.22 By inhibiting the activity of TNF, etanercept may block this cycle of inflammation, rapidly improving skin lesions. This effect is evidenced by recent observations showing that treatment with TNF antagonists results in a reduction in epidermal T-cell infiltration.19,23 In acting through a recruitment pathway, TNF antagonists reduce epidermal T-cell infiltration without causing T-cell depletion.
Etanercept has been approved for use in adults with rheumatoid arthritis since 1998 and for children with juvenile rheumatoid arthritis since 1999. Long-term clinical safety studies in more than 2000 patients and post-marketing experience in more than 150,000 patients have shown the continued efficacy and favorable risk–benefit profile of etanercept.24 Although data regarding long-term safety in patients with psoriasis are not available, the data from patients with rheumatoid arthritis suggest that long-term treatment with etanercept may be a viable option for patients with psoriasis — an important consideration in the management of this chronic disease.
Supported by Immunex, Seattle, a wholly-owned subsidiary of Amgen, Thousand Oaks, Calif.
Drs. Leonardi, Powers, Goffe, and Gottlieb report having served as consultants for Amgen, and Drs. Leonardi, Goffe, and Gottlieb report having served as paid lecturers for Amgen. Dr. Gottlieb reports having served as a consultant and paid lecturer for Johnson & Johnson, Genentech, and Biogen; Dr. Leonardi reports having served as a consultant and paid lecturer for Johnson & Johnson and Genentech; Dr. Powers reports having served as a consultant for Genentech and Biogen; and Dr. Goffe reports having served as a consultant and paid lecturer for Biogen. Dr. Zitnik and Ms. Wang report owning equity in Amgen.
We are indebted to Ann Dugan, B.S., for assistance with the conduct of the study; to Arline Nakanishi, M.S., and James Whitmore, Ph.D., for assistance with statistical content; and to Linda Melvin, B.A., and MaryAnn Foote, Ph.D., for editorial assistance.
Source Information
From the Saint Louis University School of Medicine, St. Louis (C.L.L.); Radiant Research, Scottsdale, Ariz. (J.L.P.); Oregon Medical Research Center, Portland (R.T.M.); Minor and James Medical Center, Seattle (B.S.G.); Amgen, Thousand Oaks, Calif. (R.Z., A.W.); and the University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick (A.B.G.).
Address reprint requests to Dr. Gottlieb at the University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, Clinical Research Center, 1 Robert Wood Johnson Medical School, New Brunswick, NJ 08903, or at gottliab@umdnj.edu.
Other members of the Etanercept Psoriasis Study Group are listed in the Appendix.
Appendix
Other members of the Etanercept Psoriasis Study Group include the following: J. Bagel, Psoriasis Treatment Center of Central New Jersey, East Windsor; C. Camisa, Cleveland Clinic Foundation–Florida, Naples; I. Caro, Massachusetts General Hospital, Boston; J.J. DiGiovanna, Rhode Island Hospital, Providence; F.F. Dunlap, Radiant Research, Tucson, Ariz.; B.E. Elewski, University of Alabama, Birmingham; C.E. Gribetz, Mount Sinai School of Medicine, New York; H.F. Farber, Philadelphia; S.R. Feldman, Wake Forest University School of Medicine, Winston-Salem, N.C.; E.H. Frankel, Clinical Partners, LLC, Johnston, R.I.; A.A. Gaspari, University of Maryland, Baltimore; J.J. Goodman, Radiant Research, West Palm Beach, Fla.; K.B. Gordon, Northwestern University Medical School, Chicago; F.C. Hampel, Jr., Central Texas Health Research, New Braunfels; R.S. Herdener, Physicians Clinic of Spokane, Spokane, Wash.; M.D. Hoffman, Rush–Presbyterian–St. Luke's Medical Center, Chicago; J.M. Humeniuk, Radiant Research, Greer, S.C.; S.M. Johnson, University of Arkansas for Medical Sciences, Little Rock; S. Kang, University of Michigan Medical Center, Ann Arbor; A.B. Kimball, Stanford University Medical Center, Stanford, Calif.; R.S. Kirsner, Veterans Affairs Medical Center, Miami; N.J. Korman, University Hospitals of Cleveland, Case Western Reserve University, Cleveland; G.G. Krueger, University of Utah Health Sciences Center, Salt Lake City; R.T. Kuwahara, University of Oklahoma Health Sciences Center, Oklahoma City; M. Lebwohl, Mount Sinai School of Medicine, New York; M.R. Ling, MedaPhase, Inc., Newnan, Ga.; D.C. Liu, Piedmont Medical Research Associates, Winston-Salem, N.C.; N. Lowe, Clinical Research Specialists, Inc., Santa Monica, Calif.; C.O. McCall, Emory University Hospital, Atlanta; A. Menter, Baylor University Medical Center, Dallas; B.H. Miller, Oregon Medical Research Center, Portland; J.K. Moore, Welborn Clinic, Evansville, Ind.; A.S. Nayak, Peoria School of Medicine, Normal, Ill.; P.H. Ratner, Sylvana Research, San Antonio, Tex.; R.C. Savin, The Savin Center, New Haven, Conn.; J.L. Shupack, New York University School of Medicine, New York; S.L. Smith, The Clinic, Lake Charles, La.; S.P. Stone, Southern Illinois University School of Medicine, Springfield; J.M. Swinehart, Colorado Medical Research Center, Inc., Denver; J. Taborn, Midwest Arthritis Center, Kalamazoo, Mich.; E.H. Tschen, Academic Dermatology Associates, Albuquerque, N.M.; G.D. Weinstein, University of California, Irvine; V.P. Werth, Hospital of the University of Pennsylvania, Philadelphia; P.S. Yamauchi, Clinical Research Specialists, Inc., Santa Monica, Calif.; and M.D. Zanolli, Dermatology Consultants, Nashville.
- References
References
1
Koo J . Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-496
CrossRef | Web of Science | Medline2
Finlay AY ,Coles EC . The effects of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236-244
CrossRef | Web of Science | Medline3
Krueger G ,Koo J ,Lebwohl M ,Menter A ,Stern RS ,Rolstad T . The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284
Web of Science | Medline4
Rapp SR ,Feldman SR ,Exum ML ,Fleischer AB Jr ,Reboussin DM . Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-407
CrossRef | Web of Science | Medline5
Bonifati C ,Carducci M ,Cordiali Fei P , et al. Correlated increases of tumour necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients -- relationships with disease severity. Clin Exp Dermatol 1994;19:383-387
CrossRef | Web of Science | Medline6
Ettehadi P ,Greaves MW ,Wallach D ,Aderka D ,Camp RDR . Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-151
CrossRef | Web of Science | Medline7
Mussi A ,Bonifati C ,Carducci M , et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997;11:115-118
Web of Science | Medline8
Nickoloff BJ ,Karabin GD ,Barker JN , et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991;138:129-140
Web of Science | Medline9
Bonifati C ,Ameglio F . Cytokines in psoriasis. Int J Dermatol 1999;38:241-251
CrossRef | Web of Science | Medline10
Moreland LW ,Schiff MH ,Baumgartner SW , et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-486
Web of Science | Medline11
Weinblatt ME ,Kremer JM ,Bankhurst AD , et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259
Full Text | Web of Science | Medline12
Mease PJ ,Goffe BS ,Metz J ,VanderStoep A ,Finck B ,Burge DJ . Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-390
CrossRef | Web of Science | Medline13
Mease P ,Kivitz A ,Burch F ,Siegel E ,Cohen S ,Burge D . Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a phase 3 multicenter clinical trial. Arthritis Rheum 2001;44:Suppl:S90-S90 abstract.
Web of Science14
Fredriksson T ,Pettersson U . Severe psoriasis -- oral therapy with a new retinoid. Dermatologica 1978;157:238-244
CrossRef | Medline15
Finlay AY ,Khan GK . Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216
CrossRef | Web of Science | Medline16
Moreland LW ,Baumgartner SW ,Schiff MH , et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147
Full Text | Web of Science | Medline17
Krueger GG ,Feldman SR ,Camisa C , et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-285
CrossRef | Web of Science | Medline18
Chaudhari U ,Romano P ,Mulcahy LD ,Dooley LT ,Baker DG ,Gottlieb AB . Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-1847
CrossRef | Web of Science | Medline19
Gottlieb AB ,Masud S ,Ramamurthi R , et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003;48:68-75
CrossRef | Web of Science | Medline20
Lebwohl M ,Tyring SK ,Hamilton TK , et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2002-2011
Full Text | Web of Science21
Krueger GG ,Papp KA ,Stough DB ,Loven KH ,Gulliver WP ,Ellis CN . A randomized double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-833
CrossRef | Web of Science | Medline22
Krueger JG . The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23
CrossRef | Web of Science | Medline23
Gaspari A ,Gottlieb AB ,Kang S ,Gordon K ,Feng A ,Zitnik RJ . Enbrel improves the clinical and pathologic features of psoriasis. J Invest Dermatol 2002;119:236-236 abstract.
CrossRef | Web of Science24
Moreland LW ,Cohen SB ,Klareskog L ,Sanda M ,Wajdula J ,Burge DJ . Global safety and efficacy of more than 5 years of etanercept (ENBREL) therapy in rheumatoid arthritis. Arthritis Rheum 2002;46:Suppl:S532-S532 abstract.
Web of Science
- Citing Articles (329)
Citing Articles
1
Raja K. Sivamani, Heidi Goodarzi, Miki Shirakawa Garcia, Siba P. Raychaudhuri, Lisa N. Wehrli, Yoko Ono, Emanual Maverakis. (2012) Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring. Clinical Reviews in Allergy & Immunology
CrossRef2
Johann E. Gudjonsson, Andrew Johnston, Charles N. Ellis. (2012) Novel systemic drugs under investigation for the treatment of psoriasis. Journal of the American Academy of Dermatology
CrossRef3
Danuta Gutowska-Owsiak, Graham S Ogg. (2012) The Epidermis as an Adjuvant. Journal of Investigative Dermatology
CrossRef4
Motoaki Hoshino, Taku Yoshio, Sachiko Onishi, Seiji Minota. (2011) Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Modern Rheumatology
CrossRef5
Robert S. Wallis. (2011) Biologics and Infections: Lessons from Tumor Necrosis Factor Blocking Agents. Infectious Disease Clinics of North America 25:4, 895-910
CrossRef6
Trilokraj Tejasvi, Philip E Stuart, Vinod Chandran, John J Voorhees, Dafna D Gladman, Proton Rahman, James T Elder, Rajan P Nair. (2011) TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis. Journal of Investigative Dermatology
CrossRef7
Todd A Kerensky, Alice B Gottlieb, Shimrat Yaniv, Shiu-chung Au. (2011) Etanercept: efficacy and safety for approved indications. Expert Opinion on Drug Safety1-19
CrossRef8
M. Ara, A. Pérez, J. Ferrando. (2011) Encuesta a dermatólogos sobre terapia biológica en pacientes con psoriasis moderada-grave en España. Actas Dermo-Sifiliográficas 102:9, 706-716
CrossRef9
Yung-Tsu CHO, Chien-Hung CHEN, Hsien-Yi CHIU, Tsen-Fang TSAI. (2011) Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan. The Journal of Dermatologyno-no
CrossRef10
Clio Dessinioti, Alexander J. Stratigos, Andreas Katsambas, Christina Antoniou. (2011) Anti-tumor necrosis factor-α therapies for immune-mediated and inflammatory skin diseases. Drug Development Research 72:7, 615-622
CrossRef11
C. Ferrándiz, A. García, A.J. Blasco, P. Lázaro. (2011) Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereologyno-no
CrossRef12
V. Descamps. (2011) Étanercept. Annales de Dermatologie et de Vénéréologie
CrossRef13
Ioannis D. Bassukas, Georgios Gaitanis, Max Hundeiker. (2011) Leprosy and the natural selection for psoriasis. Medical Hypotheses
CrossRef14
K. Reich, A.D. Burden, J.N. Eaton, N.S. Hawkins. (2011) Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. British Journal of Dermatologyno-no
CrossRef15
P.P.M. Van Lümig, R.J.B. Driessen, J.B.M. Boezeman, P.C.M. Van De Kerkhof, E.M.G.J. De Jong. (2011) Long-term efficacy of etanercept for psoriasis in daily practice. British Journal of Dermatologyno-no
CrossRef16
M. Ara, A. Pérez, J. Ferrando. (2011) Opinion of Spanish Dermatologists Regarding the Use of Biologic Therapy in Patients With Moderate to Severe Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 102:9, 706-716
CrossRef17
Amanda Robinson, Marisa Kardos, Alexandra B. Kimball. (2011) Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology
CrossRef18
Sang-Jun Na, Seon-Hwa So, Kee Ook Lee, Young-Chul Choi. (2011) Elevated serum level of interleukin-32α in the patients with myasthenia gravis. Journal of Neurology 258:10, 1865-1870
CrossRef19
F. Navarro-Sarabia, J. L. Fernandez-Sueiro, J. C. Torre-Alonso, J. Gratacos, R. Queiro, C. Gonzalez, E. Loza, L. Linares, P. Zarco, X. Juanola, J. Roman-Ivorra, E. Martin-Mola, R. Sanmarti, J. Mulero, G. Diaz, Y. Armendariz, E. Collantes. (2011) High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology 50:10, 1828-1837
CrossRef20
Jerry Bagel, Charles Lynde, Stephen Tyring, Gregory Kricorian, Yifei Shi, Paul Klekotka. (2011) Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept. Journal of the American Academy of Dermatology
CrossRef21
David M. Pariser, Craig L. Leonardi, Kenneth Gordon, Alice B. Gottlieb, Stephen Tyring, Kim A. Papp, Joanne Li, Scott W. Baumgartner. (2011) Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis. Journal of the American Academy of Dermatology
CrossRef22
Jashin J. Wu, Jennifer C. Channual, Frank Dann. (2011) Association of systemic psoriasis therapies and incidence of myocardial infarction. British Journal of Dermatologyno-no
CrossRef23
Caroline A. Chang, Alice B. Gottlieb, Paul F. Lizzul. (2011) Management of psoriatic arthritis from the view of the dermatologist. Nature Reviews Rheumatology
CrossRef24
Jonathan P Staidle, Tushar S Dabade, Steven R Feldman. (2011) A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opinion on Pharmacotherapy 12:13, 2041-2054
CrossRef25
C. Antoniou, T. Vergou, C. Dessinioti, A.J. Stratigos, G. Avgerinou, P. Stavropoulos, A. Katsambas. (2011) Etanercept: effectiveness and safety data of a retrospective study. Journal of the European Academy of Dermatology and Venereology 25:9, 1113-1115
CrossRef26
A.B. Gottlieb, C. Leonardi, F. Kerdel, S. Mehlis, M. Olds, D.A. Williams. (2011) Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. British Journal of Dermatology 165:3, 652-660
CrossRef27
Mark Lebwohl, Craig Leonardi, Christopher E.M. Griffiths, Jörg C. Prinz, Philippe O. Szapary, Newman Yeilding, Cynthia Guzzo, Shu Li, Ming-Chun Hsu, Bruce Strober. (2011) Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. Journal of the American Academy of Dermatology
CrossRef28
B.E. Strober, J.J. Crowley, P.S. Yamauchi, M. Olds, D.A. Williams. (2011) Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. British Journal of Dermatology 165:3, 661-668
CrossRef29
M. Inzinger, B. Heschl, W. Weger, A. Hofer, F.J. Legat, A. Gruber-Wackernagel, H. Tilz, W. Salmhofer, F. Quehenberger, P. Wolf. (2011) Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. British Journal of Dermatology 165:3, 640-645
CrossRef30
(2011) A randomized, pilot trial of etanercept in dermatomyositis. Annals of Neurology 70:3, 427-436
CrossRef31
Charles W. Lynde, Aditya K. Gupta, Lyn Guenther, Yves Poulin, Annie Levesque, Robert Bissonnette. (2011) A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. Journal of Dermatological Treatment1-7
CrossRef32
Joy Wan, Katrina Abuabara, Andrea B. Troxel, Daniel B. Shin, Abby S. Van Voorhees, Bruce F. Bebo, Gerald G. Krueger, Kristina Callis Duffin, Joel M. Gelfand. (2011) Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. Journal of the American Academy of Dermatology
CrossRef33
Kim A Papp, Gerald G Krueger, Gregor BE Jemec, Peter van de Kerkhof, Deborah Robertson, Joanne Estojak, Ronald Pedersen, Joanne Foehl, Joseph Wajdula, Robert Boggs, Charles Molta. (2011) Long-term, continuous dosing of etanercept in patients with plaque psoriasis. Expert Review of Dermatology 6:4, 361-373
CrossRef34
Bumrae Cho, Ok Jae Koo, Jong-Ik Hwang, Hwajung Kim, Eun Mi Lee, Sunghoon Hurh, Sol Ji Park, Han Ro, Jaeseok Yang, Charles D. Surh, Anthony J. dʼApice, Byeong Chun Lee, Curie Ahn. (2011) Generation of Soluble Human Tumor Necrosis Factor-α Receptor 1-Fc Transgenic Pig. Transplantation 92:2, 139-147
CrossRef35
Silas Martin, Steven R. Feldman, Matthias Augustin, Philippe Szapary, Brad Schenkel. (2011) Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. Journal of Dermatological Treatment 22:3, 138-143
CrossRef36
T. Gambichler, C. Tigges, N. Scola, J. Weber, M. Skrygan, F.G. Bechara, P. Altmeyer, A. Kreuter. (2011) Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. British Journal of Dermatology 164:6, 1383-1386
CrossRef37
Erica D. Dommasch, Katrina Abuabara, Daniel B. Shin, Josephine Nguyen, Andrea B. Troxel, Joel M. Gelfand. (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. Journal of the American Academy of Dermatology 64:6, 1035-1050
CrossRef38
C Paul, JF Stalder, D Thaçi, P Vincendon, Y Brault, D Kielar, V Tebbs. (2011) Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereologyno-no
CrossRef39
JCF van Luijn, M Danz, JWJ Bijlsma, FWJ Gribnau, HGM Leufkens. (2011) Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. Scandinavian Journal of Rheumatology 40:3, 183-191
CrossRef40
Smriti Raychaudhuri. 2011. Biologics. , 147-163.
CrossRef41
N.L. Ward, C.M. Loyd, J.A. Wolfram, D. Diaconu, C.M. Michaels, T.S. McCormick. (2011) Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. British Journal of Dermatology 164:4, 750-758
CrossRef42
Frank Bachmann, Georgios Kokolakis, Wolfram Sterry, Sandra Philipp. (2011) Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis. International Journal of Clinical Rheumatology 6:2, 135-155
CrossRef43
T. Gambichler, S. Kobus, A. Kobus, C. Tigges, N. Scola, P. Altmeyer, A. Kreuter, F.G. Bechara, M. Skrygan. (2011) Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients. Regulatory Peptides 167:2-3, 163-166
CrossRef44
2011. Specific Therapeutic Agents. , 205-317.
CrossRef45
Christopher Knight, Josephine Mauskopf, Mats Ekelund, Amitabh Singh, Shiyi Yang, Robert Boggs. (2011) Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. The European Journal of Health Economics
CrossRef46
Caitriona Ryan, Anne Bowcock, Alan Menter. (2011) Use of pharmacogenomics in psoriasis. Clinical Investigation 1:3, 399-411
CrossRef47
Anja Hänsel, Claudia Günther, Jens Ingwersen, Josephine Starke, Marc Schmitz, Michael Bachmann, Michael Meurer, Ernst Peter Rieber, Knut Schäkel. (2011) Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong Th17/Th1 T-cell responses. Journal of Allergy and Clinical Immunology 127:3, 787-794.e9
CrossRef48
H. Nagashima, K. Kaneko, A. Yamanoi, S. Motoi, S. Konakahara, J. Kohroki, Y. Masuho. (2011) TNF receptor II fusion protein with tandemly repeated Fc domains. Journal of Biochemistry 149:3, 337-346
CrossRef49
Sanjaya K. Satapathy, M. Isabel Fiel, Juan Rio Martin, Costica Aloman, Thomas D. Schiano. (2011) Hemophagocytic syndrome occurring in an adult liver transplant recipient having Still’s disease. Hepatology International 5:1, 597-602
CrossRef50
Meenu Singh, Rashmi R Das, Meenu Singh. 2011. Zinc for the common cold. .
CrossRef51
Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Michael PT Lunn, Peter Tugwell, Rachelle Buchbinder, Jasvinder A Singh. 2011. Adverse effects of biologics: a network meta-analysis and Cochrane overview. .
CrossRef52
Gabriella Nagy, Katalin Lukács, Ágnes Sziray, Katalin Fazekas, Ágnes Florián, László Tamási, Zsuzsánna Károlyi. (2011) Biológiai terápia során észlelt mellékhatások – különös tekintettel a bőrgyógyászati szövődményekre. Orvosi Hetilap 152:6, 212-220
CrossRef53
Frank O. Nestle. (2011) Psoriasis. Annual Review of Pathology: Mechanisms of Disease 7:1, 110301101326014
CrossRef54
C Antoniou, C Dessinioti, T Vergou, AJ Stratigos, G Avgerinou, M Kostaki, A Katsambas. (2010) Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis. Journal of the European Academy of Dermatology and Venereology 24:12, 1413-1420
CrossRef55
L. Puig, M. Ribera, J.M. Hernanz, I. Belinchón, J. Santos-Juanes, M. Linares, I. Querol, E. Colomé, G. Caballé. (2010) Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermo-Sifiliográficas 101:10, 827-846
CrossRef56
Elaine C. Siegfried, Lawrence F. Eichenfield, Amy S. Paller, David Pariser, Kara Creamer, Gregory Kricorian. (2010) Intermittent etanercept therapy in pediatric patients with psoriasis. Journal of the American Academy of Dermatology 63:5, 769-774
CrossRef57
Amy S. Paller, Elaine C. Siegfried, Lawrence F. Eichenfield, David Pariser, Richard G. Langley, Kara Creamer, Greg Kricorian. (2010) Long-term etanercept in pediatric patients with plaque psoriasis. Journal of the American Academy of Dermatology 63:5, 762-768
CrossRef58
Alice Gottlieb, JingYuan Feng, David J. Harrison, Denise Globe. (2010) Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology 63:4, 580-586
CrossRef59
W-H Boehncke, A Katsambas, J-P Ortonne, L Puig. (2010) EADV preceptorship: advances in dermatology. Journal of the European Academy of Dermatology and Venereology 24, 2-24
CrossRef60
James E. Signorovitch, Eric Q. Wu, Andrew P. Yu, Charles M. Gerrits, Evan Kantor, Yanjun Bao, Shiraz R. Gupta, Parvez M. Mulani. (2010) Comparative Effectiveness Without Head-to-Head Trials. PharmacoEconomics 28:10, 935-945
CrossRef61
PA Foley, C Quirk, JR Sullivan, C Dolianitis, SP Hack, K Thirunavukkarasu, AJ Cooper. (2010) Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. Journal of the European Academy of Dermatology and Venereology 24:10, 1135-1143
CrossRef62
Kim A. Papp, Yves Poulin, Robert Bissonnette, Marc Bourcier, Darryl Toth, Leslie Rosoph, Melanie Poulin-Costello, Mike Setterfield, Jerry Syrotuik. (2010) Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. Journal of the American Academy of Dermatology
CrossRef63
Manfred Kopf, Martin F. Bachmann, Benjamin J. Marsland. (2010) Averting inflammation by targeting the cytokine environment. Nature Reviews Drug Discovery 9:9, 703-718
CrossRef64
James T. Elder. (2010) What Can Psoriasis Teach Us About the Genetic Basis of Cutaneous T-Cell Lymphoma?. Clinical Lymphoma, Myeloma & Leukemia 10:0, S70-S73
CrossRef65
Marjan De Groot, Marcel B.M. Teunissen, Daisy I. Picavet, Menno A. De Rie, Jan D. Bos. (2010) Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. Experimental Dermatology 19:8, 754-756
CrossRef66
Annalisa Arcese, Nicola Aste, Alberta Bettacchi, Germana Camplone, Franca Cantoresi, Marzia Caproni, Domenico DʼAmico, Paolo Fabbri, Giorgio Filosa, Antonia Galluccio, Katharina Hansel, Paolo Lisi, Giuseppe Micali, Maria Letizia Musumeci, Massimiliano Nicolini, Aurora Parodi, Mario Patania, Michele Pezza, Concetta Potenza, Antonio Richetta, Marco Simonacci, Piergiusto Trevisan, Giancarlo Valenti, Stefano Calvieri. (2010) Treating Psoriasis with Etanercept in Italian Clinical Practice. Clinical Drug Investigation 30:8, 507-516
CrossRef67
Robert Bissonnette, Chantal Bolduc, Yves Poulin, Lyn Guenther, Charles W. Lynde, Catherine Maari. (2010) Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. Journal of the American Academy of Dermatology 63:2, 228-234
CrossRef68
Johann E Gudjonsson, Andrew Johnston, Stefan W Stoll, Mary B Riblett, Xianying Xing, James J Kochkodan, Jun Ding, Rajan P Nair, Abhishek Aphale, John J Voorhees, James T Elder. (2010) Evidence for Altered Wnt Signaling in Psoriatic Skin. Journal of Investigative Dermatology 130:7, 1849-1859
CrossRef69
Johann E Gudjonsson, Jun Ding, Andrew Johnston, Trilokraj Tejasvi, Andrew M Guzman, Rajan P Nair, John J Voorhees, Goncalo R Abecasis, James T Elder. (2010) Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with In Vitro Models. Journal of Investigative Dermatology 130:7, 1829-1840
CrossRef70
Concetto P. Agnusdei, Cristina Mastronardi. (2010) A Case of Severe Psoriasis with an Apparent Incomplete Response to Anti-Tumour Necrosis Factor Alpha Treatment. American Journal of Clinical Dermatology 11, 41-43
CrossRef71
Srdjan Prodanovich, Carlos Ricotti, Brad P. Glick, Luca Inverardi, Craig L. Leonardi, Francisco Kerdel. (2010) Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology 11, 3-9
CrossRef72
R.G. Langley, B.E. Strober, Y. Gu, S.J. Rozzo, M.M. Okun. (2010) Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. British Journal of Dermatology 162:6, 1349-1358
CrossRef73
E. Herrera, A.J. Alcaide. (2010) Uso intermitente de etanercept en psoriasis. Actas Dermo-Sifiliográficas 101, 18-25
CrossRef74
A. Zulaica, L. Pérez-Pérez, F. Allegue. (2010) Eficacia y seguridad a corto plazo de etanercept en la psoriasis. Actas Dermo-Sifiliográficas 101, 5-11
CrossRef75
V. García-Patos Briones, J. Mollet Sánchez. (2010) Eficacia y seguridad a largo plazo de etanercept en la psoriasis. Actas Dermo-Sifiliográficas 101, 12-17
CrossRef76
A Marchesoni, G Altomare, M Matucci-Cerinic, N Balato, I Olivieri, C Salvarani, T Lotti, R Scarpa, GA Vena, G Valesini, A Giannetti. (2010) An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. Journal of the European Academy of Dermatology and Venereology 24:5, 578-586
CrossRef77
Thierry Passeron, Serge Boulinguez. (2010) Quel est l’apport des nouvelles données des essais cliniques ?: Quelles leçons pour la prise en charge des patients ?. Annales de Dermatologie et de Vénéréologie 137:5, H11-H15
CrossRef78
M. Steinhoff, R. W. Groves, P. E. LeBoit, T. A. Luger. 2010. Inflammation. , 1-76.
CrossRef79
S. M. Breathnach, C. H. Smith, R. J. G. Chalmers, R. J. Hay. 2010. Systemic Therapy. , 1-53.
CrossRef80
F. Bachmann, A. Nast, W. Sterry, S. Philipp. (2010) Safety and Efficacy of the Tumor Necrosis Factor Antagonists. Seminars in Cutaneous Medicine and Surgery 29:1, 35-47
CrossRef81
Griffiths, Christopher E.M., Strober, Bruce E., van de Kerkhof, Peter, Ho, Vincent, Fidelus-Gort, Roseanne, Yeilding, Newman, Guzzo, Cynthia, Xia, Yichuan, Zhou, Bei, Li, Shu, Dooley, Lisa T., Goldstein, Neil H., Menter, Alan, . (2010) Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. New England Journal of Medicine 362:2, 118-128
Full Text82
Carlos Ferrándiz, Jose Manuel Carrascosa, Aram Boada. (2010) A new era in the management of psoriasis? The biologics: facts and controversies. Clinics in Dermatology 28:1, 81-87
CrossRef83
Simona de Portu, Micol Del Giglio, Gianfranco Altomare, Fabio Arcangeli, Enzo Berardesca, Piergiacomo Calzavara Pinton, Torello Lotti, Patrizia Martini, Andrea Peserico, Marco Simonacci, Gino A. Vena, Giampiero Girolomoni. (2010) Cost-effectiveness analysis of TNF-α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatologic Therapy 23, S7-S13
CrossRef84
M. Viguier, P. Richette, H. Bachelez, D. Wendling, F. Aubin. (2010) Manifestations cutanées paradoxales des anti-TNF-alpha. Annales de Dermatologie et de Vénéréologie 137:1, 64-71
CrossRef85
S. M. Breathnach. 2010. , 1.
CrossRef86
V. Zaragoza, A. Pérez, J.L. Sánchez, V. Oliver, L. Martínez, V. Alegre. (2010) Seguridad y eficacia de etanercept a largo plazo en el tratamiento de la psoriasis. Actas Dermo-Sifiliográficas 101:1, 47-53
CrossRef87
R.K.H. Mak, C. Hundhausen, F.O. Nestle. (2009) Progress in Understanding the Immunopathogenesis of Psoriasis. Actas Dermo-Sifiliográficas 100, 2-13
CrossRef88
E Daud
n, CEM Griffiths, J-P Ortonne, K Kragballe, CT Molta, D Robertson, R Pedersen, J Estojak, R Boggs. (2009) Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54
CrossRef89
Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples, Philippe Szapary. (2009) Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases. Annals of the New York Academy of Sciences 1182:1, 97-110
CrossRef90
J.-P. Ortonne, A. Taïeb, A.D. Ormerod, D. Robertson, J. Foehl, R. Pedersen, C. Molta, B. Freundlich. (2009) Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. British Journal of Dermatology 161:5, 1190-1195
CrossRef91
C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden, R.J.G. Chalmers, D.A. Chandler, A.Y. Finlay, C.E.M. Griffiths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds, A.D. Ormerod, . (2009) British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology 161:5, 987-1019
CrossRef92
A.J. Blasco, P. Lázaro, C. Ferrándiz, A. García-Díez, J. Liso. (2009) Eficiencia de los agentes biológicos en el tratamiento de la psoriasis moderada-grave. Actas Dermo-Sifiliográficas 100:9, 792-803
CrossRef93
Danielle Levine, Alice Gottlieb. (2009) Evaluation and Management of Psoriasis: An Internist's Guide. Medical Clinics of North America 93:6, 1291-1303
CrossRef94
D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, JD Bos, G-R Burmester, S Chimenti, L Dubertret, B Eberlein, R Erdmann, J Ferguson, G Girolomoni, P Gisondi, A Giunta, C Griffiths, H Hönigsmann, M Hussain, R Jobling, S-L Karvonen, L Kemeny, I Kopp, C Leonardi, M Maccarone, A Menter, U Mrowietz, L Naldi, T Nijsten, J-P Ortonne, H-D Orzechowski, T Rantanen, K Reich, N Reytan, H Richards, HB Thio, P van de Kerkhof, B Rzany. (2009) European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology 23, 1-70
CrossRef95
Francisco Javier Rodríguez Gil, Juan José Martínez Crespo, Daniel García Belmonte, Isabel Nicolás de Prado, Ramón de Prado Serrano. (2009) Ictericia en paciente tratada con etanercept. Gastroenterología y Hepatología 32:8, 584-585
CrossRef96
Annamaria Mazzotta, Maria Esposito, Antonio Costanzo, Sergio Chimenti. (2009) Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments. American Journal of Clinical Dermatology 10:5, 319-324
CrossRef97
J.W. Dharamsi, M. Bhosle, R. Balkrishnan, B.A. Yentzer, S.R. Feldman. (2009) Using ‘number needed to treat’ to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-α inhibitors for patients with severe psoriasis. British Journal of Dermatology 161:3, 605-616
CrossRef98
Aikaterini-Evaggelia Moustou, Athina Matekovits, Clio Dessinioti, Christina Antoniou, Petros P. Sfikakis, Alexander J. Stratigos. (2009) Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review. Journal of the American Academy of Dermatology 61:3, 486-504
CrossRef99
Eihab A. Alwawi, Eliana Krulig, Kenneth B. Gordon. (2009) Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?. Dermatologic Therapy 22:5, 431-440
CrossRef100
TA Luger, J Barker, J Lambert, S Yang, D Robertson, J Foehl, CT Molta, R Boggs. (2009) Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology 23:8, 896-904
CrossRef101
C Antoniou, C Dessinioti, A Stratigos, G Avgerinou, P Stavropoulos, A Katsambas. (2009) Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience. Journal of the European Academy of Dermatology and Venereology 23:8, 979-982
CrossRef102
Thomas Ernandez, Tanya Mayadas. (2009) Immunoregulatory role of TNFα in inflammatory kidney diseases. Kidney International 76:3, 262-276
CrossRef103
F. Prignano, F. Zanieri, S. Milani, T. Lotti. (2009) Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. Dermatologic Therapy 22:4, 386-390
CrossRef104
Manuelle Viguier, Pascal Richette, Hervé Bachelez, Daniel Wendling, François Aubin. (2009) Paradoxical adverse effects of anti-TNF-α treatment: onset or exacerbation of cutaneous disorders. Expert Review of Clinical Immunology 5:4, 421-431
CrossRef105
H Yalcin, DD Balci, E Ucar, N Ozcelik, C Tasci, E Seyfeli, F Akgul, F Yalcin. (2009) Myocardial perfusion is preserved in patients with psoriasis without clinically evident cardiovascular disease. Journal of the European Academy of Dermatology and Venereology 23:7, 798-802
CrossRef106
Anna L. Chien, James T. Elder, Charles N. Ellis. (2009) Ustekinumab. Drugs 69:9, 1141-1152
CrossRef107
L. Puig, J.M. Carrascosa, E. Daudén, J.L. Sánchez-Carazo, C. Ferrándiz, M. Sánchez-Regaña, M. García-Bustinduy, X. Bordas, J.C. Moreno, J.M. Hernanz, S. Laguarda, V. García-Patos. (2009) Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. Actas Dermo-Sifiliográficas 100:5, 386-413
CrossRef108
G. FIORINO, M. ALLEZ, A. MALESCI, S. DANESE. (2009) Review article: anti TNF-α induced psoriasis in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 29:9, 921-927
CrossRef109
J.P. McFadden, B.S. Baker, A.V. Powles, L. Fry. (2009) Psoriasis and streptococci: the natural selection of psoriasis revisited. British Journal of Dermatology 160:5, 929-937
CrossRef110
R Jiménez-Puya, F Gómez-García, V Amorrich-Campos, JC Moreno-Giménez. (2009) Etanercept: Efficacy and safety. Journal of the European Academy of Dermatology and Venereology 23:4, 402-405
CrossRef111
Erol KOC, Mustafa TUNCA, Emin Ozgur AKGUL, Ahmet AKAR, Yasemin KURT, Zafer KURUMLU, Kemal ERBIL, Selim KILIC. (2009) Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. The Journal of Dermatology 36:4, 191-196
CrossRef112
A. Levy-Roy, R. Porcher, A.-L. de Fonclare, P. Morel, A. Dupuy. (2009) Efficacité des anti-TNF-α dans le psoriasis : revue systématique et représentation graphique. Annales de Dermatologie et de Vénéréologie 136:4, 315-322
CrossRef113
Lindsay C. Strowd, Brad A. Yentzer, Alan B. Fleischer, Steven R. Feldman. (2009) Increasing use of more potent treatments for psoriasis. Journal of the American Academy of Dermatology 60:3, 478-481
CrossRef114
A. Lloyd, P. Reeves, P. Conway, A. Reynolds, G. Baxter. (2009) Economic evaluation of etanercept in the management of chronic plaque psoriasis. British Journal of Dermatology 160:2, 380-386
CrossRef115
Zhengguang Zhang, Jochen Schmitt, Gottfried Wozel, Wilhelm Kirch. (2009) Behandlung der Plaque-Psoriasis mit Biologics. Medizinische Klinik 104:2, 125-136
CrossRef116
Richard B Warren, Christopher EM Griffiths. (2009) Adalimumab for the treatment of psoriasis. Expert Review of Dermatology 4:1, 15-21
CrossRef117
Sayaka Shibata, Yayoi Tada, Mayumi Komine, Naoko Hattori, Satsuki Osame, Naoko Kanda, Shinichi Watanabe, Hidehisa Saeki, Kunihiko Tamaki. (2009) Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. Journal of Dermatological Science 53:1, 34-39
CrossRef118
P. Wolf, A. Hofer, F.J. Legat, A. Bretterklieber, W. Weger, W. Salmhofer, H. Kerl. (2009) Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. British Journal of Dermatology 160:1, 186-189
CrossRef119
Sharon A Chung, Philip Seo. (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Current Opinion in Rheumatology 21:1, 3-9
CrossRef120
R.B. Warren, B.C. Brown, D. Lavery, D.M. Ashcroft, C.E.M. Griffiths. (2009) Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. British Journal of Dermatology 160:1, 162-169
CrossRef121
Leslie Castelo-Soccio, Abby S. Van Voorhees. (2009) Long-term efficacy of biologics in dermatology. Dermatologic Therapy 22:1, 22-33
CrossRef122
Eric Q. Wu, Steve R. Feldman, Lei Chen, Anna Kaltenboeck, Andrew P. Yu, Shiraz R. Gupta, David Laitinen, Mary K. Willian. (2008) Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Current Medical Research and Opinion 24:12, 3493-3501
CrossRef123
AC Davaine, A Saraux, S Prigent, I Kupfer-Bessaguet, D Roswag, P Plantin, P Schoenlaub, F Talarmin, A Zagnoli, L Misery. (2008) Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. Journal of the European Academy of Dermatology and Venereology 22:12, 1471-1477
CrossRef124
Jean-Paul Ortonne, Christopher EM Griffiths, Esteban Daudén, Robert Strohal, Deborah Robertson, Ronald Pedersen, Charles Molta, Bruce Freundlich. (2008) Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Review of Dermatology 3:6, 657-665
CrossRef125
Marek Kurnatowski, Joanna Kudzin, Krystyna Wąsowska-Królikowska. (2008) Terapia biologiczna nieswoistych zapaleń jelit u dzieci. Pediatria Polska 83:6, 691-696
CrossRef126
Emilie Bathelier, Nathalie Gunera-Saad, Frédéric Bérard, Jean-François Nicolas. (2008) Angiokeratoma induced by injection of etanercept for psoriasis. Journal of the American Academy of Dermatology 59:5, S124-S125
CrossRef127
John C. Davis, Philip J. Mease. (2008) Insights Into the Pathology and Treatment of Spondyloarthritis: From the Bench to the Clinic. Seminars in Arthritis and Rheumatism 38:2, 83-100
CrossRef128
Rotraut Mössner, Michael P. Schön, Kristian Reich. (2008) Tumor necrosis factor antagonists in the therapy of psoriasis. Clinics in Dermatology 26:5, 486-502
CrossRef129
D. Thaçi. (2008) Long-term data in the treatment of psoriasis. British Journal of Dermatology 159, 18-24
CrossRef130
Francesca Fantuzzi, Micol Del Giglio, Paolo Gisondi, Giampiero Girolomoni. (2008) Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis. Expert Opinion on Therapeutic Targets 12:9, 1085-1096
CrossRef131
W. Gulliver. (2008) Long-term prognosis in patients with psoriasis. British Journal of Dermatology 159, 2-9
CrossRef132
M.K.A. Basra, R. Fenech, R.M. Gatt, M.S. Salek, A.Y. Finlay. (2008) The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. British Journal of Dermatology
CrossRef133
Alexa B. Kimball, Thomas S. Kupper. (2008) Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. Clinics in Dermatology 26:5, 554-561
CrossRef134
J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, W. Kirch. (2008) Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. British Journal of Dermatology 159:3, 513-526
CrossRef135
Kim A. Papp. (2008) Monitoring biologics for the treatment of psoriasis. Clinics in Dermatology 26:5, 515-521
CrossRef136
Kristian Reich. (2008) Keynote lecture: psoriasis update. Expert Review of Dermatology 3:4s, S3-S9
CrossRef137
Mao-Qiang Man, Yuejun Shi, Mona Man, Seung Hun Lee, Marianne Demerjian, Sandra Chang, Kenneth R. Feingold, Peter M. Elias. (2008) Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models. Experimental Dermatology 17:8, 681-687
CrossRef138
Jung Im NA, Jun Hyung KIM, Kyoung Chan PARK, Sang Woong YOUN. (2008) Low-dose etanercept therapy in moderate to severe psoriasis in Korean. The Journal of Dermatology 35:8, 484-490
CrossRef139
B. Strober, C. Teller, P. Yamauchi, J.L. Miller, M. Hooper, Y-C. Yang, F. Dann. (2008) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. British Journal of Dermatology 159:2, 322-330
CrossRef140
A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, A. Menter. (2008) Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. British Journal of Dermatology 159:2, 274-285
CrossRef141
Michael E. Weinblatt, Michael H. Schiff, Eric M. Ruderman, Clifton O. Bingham, Juan Li, James Louie, Daniel E. Furst. (2008) Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study. Arthritis & Rheumatism 58:7, 1921-1930
CrossRef142
P.C.M. van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, A. Kaszuba, G. Leigheb, F.M. Camacho, D. Forsea, C. Zang, M.P. Boussuge, L. Paolozzi, J. Wajdula. (2008) Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. British Journal of Dermatology???-???
CrossRef143
R.G. van Lingen, J.E.M. Körver, P.C.M. van de Kerkhof, M.A.M. Berends, D.W.A. van Rens, A.M. Langewouters, J.B.M. Boezeman, M.M.B. Seyger, E.M.G.J. de Jong. (2008) Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies. British Journal of Dermatology 159:1, 91-96
CrossRef144
William Huang, Kelly M. Cordoro, Sarah L. Taylor, Steven R. Feldman. (2008) To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. Journal of the American Academy of Dermatology 58:6, 970-977
CrossRef145
P. Gisondi, M. Del Giglio, C. Cotena, G. Girolomoni. (2008) Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. British Journal of Dermatology 158:6, 1345-1349
CrossRef146
Kristian Reich, Rodney Sinclair, Graeme Roberts, Christopher E. M. Griffiths, Maggie Tabberer, Jonathan Barker. (2008) Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Current Medical Research and Opinion 24:5, 1237-1254
CrossRef147
Alan Menter, Alice Gottlieb, Steven R. Feldman, Abby S. Van Voorhees, Craig L. Leonardi, Kenneth B. Gordon, Mark Lebwohl, John Y.M. Koo, Craig A. Elmets, Neil J. Korman, Karl R. Beutner, Reva Bhushan. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology 58:5, 826-850
CrossRef148
R.J.B. Driessen, M.A.M. Berends, J.B. Boezeman, P.C.M. van de Kerkhof, E.M.G.J. de Jong. (2008) Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. British Journal of Dermatology 158:5, 1098-1106
CrossRef149
Joel M. Gelfand, Alexa B. Kimball, Eliot N. Mostow, Chiun-Fang Chiou, Vaishali Patel, H. Amy Xia, Bruce Freundlich, Seth R. Stevens. (2008) Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment. Value in Health 11:3, 400-407
CrossRef150
Erin Ducharme, Jeffrey M Weinberg. (2008) Etanercept. Expert Opinion on Biological Therapy 8:4, 491-502
CrossRef151
Marina Papoutsaki, Antonio Costanzo, Maria-Sole Chimenti, Sergio Chimenti. (2008) Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opinion on Biological Therapy 8:3, 363-370
CrossRef152
J.-H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, J.-P. Ortonne, K. Unnebrink, M. Kaul, A. Camez, . (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). British Journal of Dermatology 158:3, 558-566
CrossRef153
D. Revicki, M.K. Willian, J.-H. Saurat, K.A. Papp, J.-P. Ortonne, C. Sexton, A. Camez. (2008) Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. British Journal of Dermatology 158:3, 549-557
CrossRef154
E.J. Giamarellos-Bourboulis, E. Pelekanou, A. Antonopoulou, H. Petropoulou, F. Baziaka, V. Karagianni, N. Stavrianeas, H. Giamarellou. (2008) An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. British Journal of Dermatology 158:3, 567-572
CrossRef155
Malini Patel Galindo, Brenda L Bartlett, Aron Gewirtzman, Natalia Mendoza, Anne Marie Tremaine, Stephen K Tyring. (2008) Etanercept: an overview of its role in the treatment of psoriasis. Expert Opinion on Drug Metabolism & Toxicology 4:3, 305-310
CrossRef156
Daniel Tracey, Lars Klareskog, Eric H. Sasso, Jochen G. Salfeld, Paul P. Tak. (2008) Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology & Therapeutics 117:2, 244-279
CrossRef157
Paller, Amy S., Siegfried, Elaine C., Langley, Richard G., Gottlieb, Alice B., Pariser, David, Landells, Ian, Hebert, Adelaide A., Eichenfield, Lawrence F., Patel, Vaishali, Creamer, Kara, Jahreis, Angelika, . (2008) Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. New England Journal of Medicine 358:3, 241-251
Full Text158
Yoshinori Umezawa. (2008) TNF.ALPHA. inhibitors treatments for Psoriasis. Inflammation and Regeneration 28:1, 27-30
CrossRef159
JR Bradley. (2008) TNF-mediated inflammatory disease. The Journal of Pathology 214:2, 149-160
CrossRef160
Laurence Le Cleach, Olivier Chassany, Annabelle Levy, Pierre Wolkenstein, Olivier Chosidow. (2008) Poor Reporting of Quality of Life Outcomes in Dermatology Randomized Controlled Clinical Trials. Dermatology 216:1, 46-55
CrossRef161
Dennis A. Revicki, Mary K. Willian, Alan Menter, Jean-Hilaire Saurat, Neesha Harnam, Martin Kaul. (2008) Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis. Dermatology 216:3, 260-270
CrossRef162
Jan Lin, David Ziring, Sheetal Desai, Sungjin Kim, Maida Wong, Yael Korin, Jonathan Braun, Elaine Reed, David Gjertson, Ram Raj Singh. (2008) TNFα blockade in human diseases: An overview of efficacy and safety. Clinical Immunology 126:1, 13-30
CrossRef163
Shusheng Geng, Hong Chang, Weisong Qin, Yan Li, Jiannan Feng, Beifen Shen. (2007) Overexpression, Effective Renaturation, and Bioactivity of Novel Single‐Chain Antibodies Against TNF‐α. Preparative Biochemistry and Biotechnology 38:1, 74-86
CrossRef164
Jeff Hick, Steven R. Feldman. (2007) Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatments. Journal of the American Academy of Dermatology 57:6, 972-976
CrossRef165
A. Sparsa. (2007) Étanercept : Enbrel®. Annales de Dermatologie et de Vénéréologie 134:12, 972-977
CrossRef166
C F McTiernan, M A Mathier, X Zhu, X Xiao, E Klein, C H Swan, H Mehdi, G Gibson, A M Trichel, J C Glorioso, A M Feldman, K R McCurry, B London. (2007) Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Therapy 14:23, 1613-1622
CrossRef167
Gerhard Schmid-Ott, Sabine Schallmayer, Iris Tatjana Calliess. (2007) Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clinics in Dermatology 25:6, 547-554
CrossRef168
L. Mahiques, G. Pitarch, J.L. Sánchez-Carazo, A. Pérez-Ferriols, C.J. Soriano, V. Alegre. (2007) Estudio de las poblaciones linfocitarias en las lesiones de psoriasis tras el bloqueo del factor de necrosis tumoral alfa con etanercept. Actas Dermo-Sifiliográficas 98:8, 539-544
CrossRef169
Zhanju Liu, Jinxia Jiu, Shuman Liu, Xianen Fa, Fuguang Li, Ying Du. (2007) Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. Journal of Autoimmunity 29:2-3, 187-194
CrossRef170
Wolf-Henning Boehncke. (2007) Etanercept: a soluble TNF-α receptor in the treatment of psoriasis. Therapy 4:5, 665-672
CrossRef171
Tatjana Heinen-Kammerer, Dietmar Daniel, Lioba Stratmann, Reinhard Rychlik, Wolf-Henning Boehncke. (2007) Cost-effectiveness of psoriasis therapy with etanercept in Germany. JDDG 5:9, 762-768
CrossRef172
Paolo Gisondi, Giampiero Girolomoni. (2007) Biologic therapies in psoriasis: A new therapeutic approach. Autoimmunity Reviews 6:8, 515-519
CrossRef173
Stern, Robert S., . (2007) Psoralen and Ultraviolet A Light Therapy for Psoriasis. New England Journal of Medicine 357:7, 682-690
Full Text174
Alan Menter, Christopher EM Griffiths. (2007) Current and future management of psoriasis. The Lancet 370:9583, 272-284
CrossRef175
Christopher EM Griffiths, Jonathan NWN Barker. (2007) Pathogenesis and clinical features of psoriasis. The Lancet 370:9583, 263-271
CrossRef176
Alan S. Boyd. (2007) Etanercept Treatment of Erythema Nodosum. SKINmed 6:4, 197-199
CrossRef177
Alexander Nast, Ina B. Kopp, Matthias Augustin, Kirstin-Benita Banditt, Wolf-Henning Boehncke, Markus Follmann, Markus Friedrich, Matthias Huber, Christina Kahl, Joachim Klaus, Joachim Koza, Inga Kreiselmaier, Johannes Mohr, Ulrich Mrowietz, Hans-Michael Ockenfels, Hans-Dieter Orzechowski, Jörg Prinz, Kristian Reich, Thomas Rosenbach, Stefanie Rosumeck, Martin Schlaeger, Gerhard Schmid-Ott, Michael Sebastian, Volker Streit, Tobias Weberschock, Berthold Rzany. (2007) Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. JDDG 5:s3, 1-119
CrossRef178
Hong Chang, Weisong Qin, Yan Li, Jiyan Zhang, Zhou Lin, Ming Lv, Yingxun Sun, Jiannan Feng, Beifen Shen. (2007) A novel human scFv fragment against TNF-α from de novo design method. Molecular Immunology 44:15, 3789-3796
CrossRef179
Gino A Vena, Nicoletta Cassano. (2007) Anti-tumor necrosis factor therapies for psoriasis. Expert Review of Dermatology 2:3, 335-349
CrossRef180
Johann E Gudjonsson, Andrew Johnston, Melissa Dyson, Helgi Valdimarsson, James T Elder. (2007) Mouse Models of Psoriasis. Journal of Investigative Dermatology 127:6, 1292-1308
CrossRef181
A. Nast, I. Kopp, M. Augustin, K. B. Banditt, W. H. Boehncke, M. Follmann, M. Friedrich, M. Huber, C. Kahl, J. Klaus, J. Koza, I. Kreiselmaier, J. Mohr, U. Mrowietz, H. M. Ockenfels, H. D. Orzechowski, J. Prinz, K. Reich, T. Rosenbach, S. Rosumeck, M. Schlaeger, G. Schmid-Ott, M. Sebastian, V. Streit, T. Weberschock, B. Rzany. (2007) German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Archives of Dermatological Research 299:3, 111-138
CrossRef182
J. Braun, X. Baraliakos, J. Listing, J. Davis, D. van der Heijde, H. Haibel, M. Rudwaleit, J. Sieper. (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents. Arthritis & Rheumatism 57:4, 639-647
CrossRef183
Jennifer K Tan, Abhishek Aphale, Rama Malaviya, Yvonne Sun, Alice B Gottlieb. (2007) Mechanisms of Action of Etanercept in Psoriasis. Journal of Investigative Dermatology Symposium Proceedings 12:1, 38-45
CrossRef184
K. Ahmad, S. Rogers. (2007) Two years of experience with etanercept in recalcitrant psoriasis. British Journal of Dermatology 156:5, 1010-1014
CrossRef185
Jeannine Koay Hoang, Jyoti Burruss. (2007) Localized Cutaneous Cryptococcus albidus Infection in a 14-Year-Old Boy on Etanercept Therapy. Pediatric Dermatology 24:3, 285-288
CrossRef186
Alice B Gottlieb. (2007) Tumor Necrosis Factor Blockade: Mechanism of Action. Journal of Investigative Dermatology Symposium Proceedings 12:1, 1-4
CrossRef187
R.P. Katugampola, V.J. Lewis, A.Y. Finlay. (2007) The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. British Journal of Dermatology 156:5, 945-950
CrossRef188
PANAGIOTIS G. THEODOSSIADIS, NIKOLAOS N. MARKOMICHELAKIS, PETROS P. SFIKAKIS. (2007) TUMOR NECROSIS FACTOR ANTAGONISTS. Retina 27:4, 399-413
CrossRef189
Xiao-Tao Chen, Bahman Ghavimi, Ronald L. Corbett, Chu-Biao Xue, Rui-Qin Liu, Maryanne B. Covington, Mingxin Qian, Krishna G. Vaddi, David D. Christ, Karl D. Hartman, Maria D. Ribadeneira, James M. Trzaskos, Robert C. Newton, Carl P. Decicco, James J.-W. Duan. (2007) A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1′ group for the β-amino hydroxamic acid derived TACE inhibitors. Bioorganic & Medicinal Chemistry Letters 17:7, 1865-1870
CrossRef190
A. Cavailhes, S. Ingen-Housz-Oro, S. Djennane, M. Rafaa, F. Fiszenson-Albala, N. Weber, M. Sigal-Grinberg. (2007) Survenue d’un psoriasis au cours d’un traitement par infliximab pour fasciite de Shulman. Annales de Dermatologie et de Vénéréologie 134:4, 363-367
CrossRef191
Juan Jorge Manriquez, Maria Francisca Villouta, Hywel C. Williams. (2007) Evidence-based dermatology: Number needed to treat and its relation to other risk measures. Journal of the American Academy of Dermatology 56:4, 664-671
CrossRef192
Angela Moore, Kenneth B. Gordon, Sewon Kang, Alice Gottlieb, Bruce Freundlich, H. Amy Xia, Seth R. Stevens. (2007) A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. Journal of the American Academy of Dermatology 56:4, 598-603
CrossRef193
Argentina Leon, Alain Nguyen, Julie Letsinger, John Koo. (2007) An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Expert Opinion on Pharmacotherapy 8:5, 617-632
CrossRef194
Kim A Papp. (2007) The safety of etanercept for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management 3:2, 245-258
CrossRef195
Shanu Kohli Kurd, Stephen K Richardson, Joel M Gelfand. (2007) Update on the epidemiology and systemic treatment of psoriasis. Expert Review of Clinical Immunology 3:2, 171-185
CrossRef196
Weisong Qin, Jiannan Feng, Yan Li, Zhou Lin, Beifen Shen. (2007) A novel domain antibody rationally designed against TNF-α using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides. Molecular Immunology 44:9, 2355-2361
CrossRef197
Jochen Schmitt, Daniel E. Ford. (2007) Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis — a structural equations modeling approach. General Hospital Psychiatry 29:2, 134-140
CrossRef198
Krueger, Gerald G., Langley, Richard G., Leonardi, Craig, Yeilding, Newman, Guzzo, Cynthia, Wang, Yuhua, Dooley, Lisa T., Lebwohl, Mark, . (2007) A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis. New England Journal of Medicine 356:6, 580-592
Full Text199
M. Hochberg, S. Zeligson, N. Amariglio, G. Rechavi, A. Ingber, C.D. Enk. (2007) Genomic-scale analysis of psoriatic skin reveals differentially expressed insulin-like growth factor-binding protein-7 after phototherapy. British Journal of Dermatology 156:2, 289-300
CrossRef200
Gilles Safa, Marion Loppin, Anne-Marie Bousser, Sebastien Barbarot. (2007) Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis. Journal of the American Academy of Dermatology 56:2, S19-S20
CrossRef201
R.J. Ludwig, C. Herzog, A. Rostock, F.R. Ochsendorf, T.M. Zollner, D. Thaci, R. Kaufmann, T.J. Vogl, W-H. Boehncke. (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. British Journal of Dermatology 156:2, 271-276
CrossRef202
Akiko Nishibu, Brant R. Ward, Marianne Boes, Akira Takashima. (2007) Roles for IL-1 and TNFα in dynamic behavioral responses of Langerhans cells to topical hapten application. Journal of Dermatological Science 45:1, 23-30
CrossRef203
2007. Management of Psoriatic Arthritis. , 97-113.
CrossRef204
Stephanie Diamantis, Mark Lebwohl. 2007. Dermatologic Management of Psoriasis. , 114-121.
CrossRef205
Cristina Carrera, Jose M. Mascaró Jr., Juan A. Moreno-Romero, Pilar Iranzo, Josep Palou, Esther Zamora, Carmen Herrero. (2007) Pyoderma Vegetans Associated with Severe Psoriatic Arthritis: Good Response to Etanercept. Dermatology 214:1, 77-81
CrossRef206
B. Elewski, C. Leonardi, A.B. Gottlieb, B.E. Strober, M.A. Simiens, M. Dunn, A. Jahreis. (2007) Comparison of clinical and pharmacokinetic profiles of etanercept 25
CrossRef207
Niko K. Bender, Christoph E. Heilig, Benjamin Dröll, Jessica Wohlgemuth, Franz-Paul Armbruster, Bernhard Heilig. (2006) Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatology International 27:3, 269-274
CrossRef208
Sandra Philipp, Kerstin Wolk, Stephanie Kreutzer, Elizabeth Wallace, Nina Ludwig, Joachim Roewert, Conny Höflich, Hans-Dieter Volk, Wolfram Sterry, Robert Sabat. (2006) The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opinion on Therapeutic Targets 10:6, 817-831
CrossRef209
Arisa Ortiz, Paul S. Yamauchi. (2006) A Treatment Strategy for Psoriasis: Transitioning From Systemic Therapy to Biologic Agents. SKINmed 5:6, 285-290
CrossRef210
Alexander Nast, Ina B. Kopp, Matthias Augustin, Kirstin-Benita Banditt, Wolf-Henning Boehncke, Markus Follmann, Markus Friedrich, Matthias Huber, Christina Kahl, Joachim Klaus, Joachim Koza, Inga Kreiselmaier, Johannes Mohr, Ulrich Mrowietz, Hans-Michael Ockenfels, Hans-Dieter Orzechowski, Jörg Prinz, Kristian Reich, Thomas Rosenbach, Stefanie Rosumeck, Martin Schlaeger, Gerhard Schmid-Ott, Michael Sebastian, Volker Streit, Tobias Weberschock, Berthold Rzany. (2006) S3-Leitlinie zur Therapie der Psoriasis vulgaris. Journal der Deutschen Dermatologischen Gesellschaft 4, S1-S126
CrossRef211
P Wolkenstein. (2006) Living with psoriasis. Journal of the European Academy of Dermatology and Venereology 20:s2, 28-32
CrossRef212
Michael R Lee, Alan J Cooper. (2006) Biologic agents in psoriasis. Australasian Journal of Dermatology 47:4, 217-230
CrossRef213
Ivan Nestorov, Ralph Zitnik, Todd DeVries, Arline M. Nakanishi, Andrea Wang, Christopher Banfield. (2006) Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. British Journal of Clinical Pharmacology 62:4, 435-445
CrossRef214
M. de Groot, M. Appelman, P.I. Spuls, M.A. de Rie, J.D. Bos. (2006) Initial experience with routine administration of etanercept in psoriasis. British Journal of Dermatology 155:4, 808-814
CrossRef215
Robert Orenstein. (2006) Infections related to TNF-α inhibitors. Expert Review of Dermatology 1:5, 737-749
CrossRef216
Wendy A. Myers, Alice B. Gottlieb, Philip Mease. (2006) Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clinics in Dermatology 24:5, 438-447
CrossRef217
W-H Boehncke, RA Brasie, J Barker, S Chimenti, E Dauden, M de Rie, L Dubertret, A Giannetti, A Katsambas, K Kragballe, JM Naeyaert, J-P Ortonne, J Peyri, JC Prinz, J-H Saurat, R Strohal, P van de Kerkhof, W Sterry. (2006) Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. Journal of the European Academy of Dermatology and Venereology 0:0, 060804053334002-???
CrossRef218
Weisong Qin, Jiannan Feng, Yan Li, Zhou Lin, Beifen Shen. (2006) De novo design TNF-α antagonistic peptide based on the complex structure of TNF-α with its neutralizing monoclonal antibody Z12. Journal of Biotechnology 125:1, 57-63
CrossRef219
Spyros Aslanidis, Athina Pyrpasopoulou, Maria Leontsini, Chryssanthos Zamboulis. (2006) Anti-TNF-α-induced psoriasis: Case report of an unusual adverse event. International Journal of Dermatology 45:8, 982-983
CrossRef220
Alex V. Anstey, Knud Kragballe. (2006) Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. International Journal of Dermatology 45:8, 970-975
CrossRef221
Rotraut Mössner, Kristian Reich. (2006) Infliximab in the treatment of psoriasis. Expert Review of Dermatology 1:4, 515-526
CrossRef222
Noah Gratch, Jeffrey M Weinberg, Andrew F Alexis. (2006) Etanercept: a tumor necrosis factor inhibitor for psoriasis and psoriatic arthritis. Expert Review of Dermatology 1:4, 527-534
CrossRef223
PCM van de Kerkhof. (2006) Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. Journal of the European Academy of Dermatology and Venereology 20:6, 639-650
CrossRef224
M. Esposito, A. Mazzotta, C. de Felice, M. Papoutsaki, S. Chimenti. (2006) Treatment of erythrodermic psoriasis with etanercept. British Journal of Dermatology 155:1, 156-159
CrossRef225
J. Pfeffer, R. Kaufmann, W.-H. Boehncke. (2006) Psoriasis-SCID-Maus-Modell. Der Hautarzt 57:7, 603-609
CrossRef226
Alexander J Stratigos, Petros P Sfikakis. (2006) Psoriasis occurring during anti-TNF-α therapy: causal effect or unrelated?. Future Rheumatology 1:3, 281-284
CrossRef227
Kim A. Papp. (2006) The long-term efficacy and safety of new biological therapies for psoriasis. Archives of Dermatological Research 298:1, 7-15
CrossRef228
Sanjay M Rajpara, Anthony D Ormerod, Pick N Woo. (2006) Biological treatments for psoriasis. Therapy 3:3, 425-436
CrossRef229
John H. Stone, Janet T. Holbrook, Matthew A. Marriott, Andrea K. Tibbs, Lourdes P. Sejismundo, Y.-I. Min, Ulrich Specks, Peter A. Merkel, Robert Spiera, John C. Davis, E. William St.Clair, W. Joseph McCune, Steven R. Ytterberg, Nancy B. Allen, Gary S. Hoffman, . (2006) Solid malignancies among patients in the Wegener's granulomatosis etanercept trial. Arthritis & Rheumatism 54:5, 1608-1618
CrossRef230
William D Tutrone, Jeffrey M Weinberg. (2006) Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept. Expert Review of Dermatology 1:2, 207-216
CrossRef231
Lily Yi Li, Angela K Brimhall, Alan Menter. (2006) Systemic therapy for moderate-to-severe psoriasis. Expert Review of Dermatology 1:1, 77-92
CrossRef232
Weisong Qin, Jiannan Feng, Yan Li, Zhou Lin, Beifen Shen. (2006) Fusion protein of CDR mimetic peptide with Fc inhibit TNF-α induced cytotoxicity. Molecular Immunology 43:6, 660-666
CrossRef233
Drew W Miller, Steven R Feldman. (2006) Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opinion on Pharmacotherapy 7:2, 157-167
CrossRef234
C. Cusack, C. Buckley. (2006) Etanercept: effective in the management of hidradenitis suppurativa. British Journal of Dermatology 0:0, 060116091018022
CrossRef235
Jochen M. Schmitt, Daniel E. Ford. (2006) Work Limitations and Productivity Loss Are Associated with Health-Related Quality of Life but Not with Clinical Severity in Patients with Psoriasis. Dermatology 213:2, 102-110
CrossRef236
Aimee C. Hawrot, Denise W. Metry, Amy J. Theos, Moise L. Levy. (2006) Etanercept for Psoriasis in the Pediatric Population: Experience in Nine Patients. Pediatric Dermatology 23:1, 67-71
CrossRef237
Daniel J. Pearce, Andrew A. Nelson, Alan B. Fleischer, Rajesh Balkrishnan, Steven R. Feldman. (2006) The cost‐effectiveness and cost of treatment failures associated with systemic psoriasis therapies. Journal of Dermatological Treatment 17:1, 29-37
CrossRef238
Kenneth B. Gordon, Alice B. Gottlieb, Craig L. Leonardi, Boni E. Elewski, Andrea Wang, Angelika Jahreis, Ralph Zitnik. (2006) Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. Journal of Dermatological Treatment 17:1, 9-17
CrossRef239
Giuseppe Vittorio Luigi De Socio, Stefano Simonetti, Giuliano Stagni. (2006) Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scandinavian Journal of Infectious Diseases 38:1, 74-75
CrossRef240
Reyes Gamo, José L. López-Estebaranz. (2006) Terapia biológica y psoriasis. Actas Dermo-Sifiliográficas 97:1, 1-17
CrossRef241
M. Papoutsaki, A. Costanzo, A. Mazzotta, T. Gramiccia, R. Soda, S. Chimenti. (2006) Etanercept for the treatment of severe childhood psoriasis. British Journal of Dermatology 154:1, 181-183
CrossRef242
Stephen Tyring, Alice Gottlieb, Kim Papp, Ken Gordon, Craig Leonardi, Andrea Wang, Deepa Lalla, Michael Woolley, Angelika Jahreis, Ralph Zitnik, David Cella, Ranga Krishnan. (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. The Lancet 367:9504, 29-35
CrossRef243
Amos Gilhar, Ron Yaniv, Bedia Assy, Sima Serafimovich, Yehuda Ullmann, Richard S. Kalish. (2006) Fas Pulls the Trigger on Psoriasis. The American Journal of Pathology 168:1, 170-175
CrossRef244
Florence Tubach, Dominique Salmon-Céron, Philippe Ravaud, Xavier Mariette. (2005) The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFα therapy. Joint Bone Spine 72:6, 456-460
CrossRef245
Philippe Goupille. (2005) Psoriatic arthritis. Joint Bone Spine 72:6, 466-470
CrossRef246
Richard G. Langley, Vincent Ho, Charles Lynde, Kim A. Papp, Yves Poulin, Neil Shear, Jack Toole, Catherine Zip. (2005) Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. Journal of Cutaneous Medicine and Surgery 9:S1, 18-25
CrossRef247
K.B. Gordon, B.K. Bonish, T. Patel, C.L. Leonardi, B.J. Nickoloff. (2005) The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. British Journal of Dermatology 153:5, 945-953
CrossRef248
A. Sparsa. (2005) Etanercept. Annales de Dermatologie et de Vénéréologie 132:11, 861-876
CrossRef249
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher EM Griffiths. (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. The Lancet 366:9494, 1367-1374
CrossRef250
Stamatis-Nick C. Liossis, George C. Tsokos. (2005) Monoclonal antibodies and fusion proteins in medicine. Journal of Allergy and Clinical Immunology 116:4, 721-729
CrossRef251
Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin, Eric M. Ruderman, Serge D. Steinfeld, Ernest H.S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok, Mark A. Weinberg, . (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis & Rheumatism 52:10, 3279-3289
CrossRef252
Anton Alexandroff Vrach, Muzlifah Haniffa, Clifford Lawrence, Suzy Leech. 2005. Drugs for the Treatment of Specific Skin Diseases. , 325-344.
CrossRef253
G. Wozel. (2005) Etanercept. Der Hautarzt 56:9, 819-830
CrossRef254
C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden, R.J.G. Chalmers, D. Chandler, A.Y. Finlay, C.E.M. Grifitths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds, A.D. Ormerod, . (2005) British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology 153:3, 486-497
CrossRef255
Mathias Grunke, Joachim Robert Kalden. (2005) Etanercept: an introduction. Expert Review of Clinical Immunology 1:3, 313-323
CrossRef256
J.-P. Ortonne. (2005) Prise en charge thérapeutique du psoriasis en plaques : apport des anti-TNFα. Annales de Dermatologie et de Vénéréologie 132:8-9, 6-9
CrossRef257
David J. Rychly, Joseph T. DiPiro. (2005) Infections Associated with Tumor Necrosis Factor-α Antagonists. Pharmacotherapy 25:9, 1181-1192
CrossRef258
Samir Malhotra, Dipika Bansal, Nusrat Shafiq, Promila Pandhi, Bhushan Kumar. (2005) Potential therapeutic role of peroxisome proliferator activated receptor-γ agonists in psoriasis. Expert Opinion on Pharmacotherapy 6:9, 1455-1461
CrossRef259
Sharon E. Jacob, Amanda Sergay, Francisco A. Kerdel. (2005) Etanercept and psoriasis, from clinical studies to real life. International Journal of Dermatology 44:8, 688-691
CrossRef260
Philip J Mease. (2005) Psoriatic arthritis therapy advances. Current Opinion in Rheumatology 17:4, 426-432
CrossRef261
Ming-Sing Si, Bruce A. Reitz, Dominic C. Borie. (2005) Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-α production. International Immunopharmacology 5:7-8, 1141-1149
CrossRef262
Celia Dominguez, Nuria Tamayo, Dawei Zhang. (2005) p38 Inhibitors: beyond pyridinylimidazoles. Expert Opinion on Therapeutic Patents 15:7, 801-816
CrossRef263
Kenneth R. Kaufman. (2005) Etanercept, anticytokines and mania. International Clinical Psychopharmacology 20:4, 239-241
CrossRef264
Eric L. Matteson, Hyon K. Choi, Dennis S. Poe, Christopher Wise, Val J. Lowe, Thomas J. Mcdonald, Mahboob U. Rahman. (2005) Etanercept therapy for immune-mediated cochleovestibular disorders: A multi-center, open-label, pilot study. Arthritis & Rheumatism 53:3, 337-342
CrossRef265
Mohanad Bakleh, Imad Tleyjeh, Eric L. Matteson, Douglas R. Osmon, Elie F. Berbari. (2005) Infectious complications of tumor necrosis factor-α antagonists. International Journal of Dermatology 44:6, 443-448
CrossRef266
Marc C. Hochberg, Mark G. Lebwohl, Scott E. Plevy, Kathryn F. Hobbs, David E. Yocum. (2005) The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Seminars in Arthritis and Rheumatism 34:6, 819-836
CrossRef267
K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E.M. Griffiths, A.M. Nakanishi, R. Zitnik, P.C.M. van de Kerkhof, . (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. British Journal of Dermatology 152:6, 1304-1312
CrossRef268
A.B. Gottlieb, C.E.M. Griffiths, V.C. Ho, M. Lahfa, U. Mrowietz, D.F. Murrell, J-P. Ortonne, G. Todd, R. Cherill, I. Marks, S. Emady-Azar, C.F. Paul, . (2005) Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. British Journal of Dermatology 152:6, 1219-1227
CrossRef269
Schön, Michael P., Boehncke, W.-Henning, . (2005) Psoriasis. New England Journal of Medicine 352:18, 1899-1912
Full Text270
A.Y. Finlay. (2005) Current severe psoriasis and the Rule of Tens. British Journal of Dermatology 152:5, 861-867
CrossRef271
Christopher E. M. Griffiths. (2005) Controversies in Experimental Dermatology. Viewpoint 5. Experimental Dermatology 14:5, 398-399
CrossRef272
Koichi Yokota, Shin-Ichiro Nishimura. (2005) MMP/ADAM inhibitors: therapeutic potential for psoriasis. Expert Opinion on Therapeutic Patents 15:4, 421-435
CrossRef273
R. Weller. (2005) U.S. experience of immunomodulators in the treatment of psoriasis. British Journal of Dermatology 152:4, 817-818
CrossRef274
Christian E. Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R. Burmester, Udo Schneider, Daniel E. Furst, Jerry Molitor, Edward Keystone, Dafna Gladman, Bernhard Manger, Siegfried Wassenberg, Ralf Weier, Daniel J. Wallace, Michael H. Weisman, Joachim R. Kalden, Josef Smolen. (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis & Rheumatism 52:4, 1227-1236
CrossRef275
Boulos Haraoui. (2005) Differentiating the efficacy of the tumor necrosis factor inhibitors. Seminars in Arthritis and Rheumatism 34:5, 7-11
CrossRef276
Jennifer Clay Cather, Alan Menter. (2005) Efalizumab: continuous therapy for chronic psoriasis. Expert Opinion on Biological Therapy 5:3, 393-403
CrossRef277
M. Perossini, E. Turio, T. Perossini, M. Romagnoli, S. Benedetti, G. Cei, P. Barachini, M. Nardi. (2005) Pattern VEP Alterations in Psoriatic Patients may Indicate a Sub Clinic Optic Neuritis. Documenta Ophthalmologica 110:2-3, 203-207
CrossRef278
K STEIN, D PEARCE, S FELDMAN. (2005) The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Seminars in Cutaneous Medicine and Surgery 24:1, 52-57
CrossRef279
B STROBER. (2005) The treatment of psoriasis with etanercept. Seminars in Cutaneous Medicine and Surgery 24:1, 28-36
CrossRef280
Petros Efthimiou, Joseph A. Markenson. (2005) Role of Biological Agents in Immune-mediated Inflammatory Diseases. Southern Medical Journal 98:2, 192-204
CrossRef281
Melissa A Magliocco. (2005) Emerging drugs for moderate-to-severe psoriasis. Expert Opinion on Emerging Drugs 10:1, 35-52
CrossRef282
The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. (2005) Etanercept plus Standard Therapy for Wegener's Granulomatosis. New England Journal of Medicine 352:4, 351-361
Full Text283
Andrew A. Nelson, Daniel J. Pearce, Alan B. Fleischer Jr, Rajesh Balkrishnan, Steven R. Feldman. (2005) Infliximab for inpatient psoriasis management – is there a role?. Journal of Dermatological Treatment 16:5-6, 314-318
CrossRef284
David A Fairhurst, Darren M Ashcroft, Christopher EM Griffiths. (2005) Optimal Management of Severe Plaque Form of Psoriasis. American Journal of Clinical Dermatology 6:5, 283-294
CrossRef285
Mark G Lebwohl. (2005) Use of Etanercept in the Dermatology Setting. American Journal of Clinical Dermatology 6:1, 49-59
CrossRef286
Hervé Bachelez. (2005) Immunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity. Journal of Autoimmunity 25, 69-73
CrossRef287
Alice B. Gottlieb. (2005) Psoriasis: emerging therapeutic strategies. Nature Reviews Drug Discovery 4:1, 19-34
CrossRef288
Samuel L. Moschella. (2005) Is There a Role for Tumor Necrosis Factor-? Inhibitors and Especially Thalidomide in Dermatology?. SKINmed 4:1, 24-32
CrossRef289
Soo-Hyun Kim, Sun-Young Han, Tania Azam, Do-Young Yoon, Charles A. Dinarello. (2005) Interleukin-32. Immunity 22:1, 131-142
CrossRef290
Selwyn Chow, Carina Rizzo, Larisa Ravitskiy, Animesh A. Sinha. (2005) The role of T cells in cutaneous autoimmune disease. Autoimmunity 38:4, 303-317
CrossRef291
V Schleyer, M Landthaler, R-M Szeimies. (2005) Novel pharmacological approaches in the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology 19:1, 1-20
CrossRef292
(2005) Safety and efficacy study on etanercept in patients with plaque psoriasis. British Journal of Dermatology 152:1, 187-189
CrossRef293
Abdul B. Lodhi, John D. Carter, Joanne Valeriano, Frank B. Vasey. (2004) Can we classify psoriatic arthritis?. Seminars in Arthritis and Rheumatism 34:3, 571-572
CrossRef294
Frank O. Nestle, Curdin Conrad. (2004) The IL-12 Family Member p40 Chain as a Master Switch and Novel Therapeutic Target in Psoriasis. Journal of Investigative Dermatology 123:6, xiv-xv
CrossRef295
Ivan Nestorov, Ralph Zitnik, Thomas Ludden. (2004) Population Pharmacokinetic Modeling of Subcutaneously Administered Etanercept in Patients with Psoriasis. Journal of Pharmacokinetics and Pharmacodynamics 31:6, 463-490
CrossRef296
Catharine L. Kauffman, Nancy Aria, Eiko Toichi, Thomas S. McCormick, Kevin D. Cooper, Alice B. Gottlieb, Daniel E. Everitt, Bart Frederick, Yaowei Zhu, Martin A. Graham, Charles E. Pendley, Mary Ann Mascelli. (2004) A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis. Journal of Investigative Dermatology 123:6, 1037-1044
CrossRef297
Peter C Taylor, Richard O Williams, Marc Feldmann. (2004) Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases. Current Opinion in Biotechnology 15:6, 557-563
CrossRef298
Richard Groves. (2004) Cytokine and anti-cytokine therapy in the treatment of inflammatory skin disease. Cytokine 28:4-5, 162-166
CrossRef299
Christine Della Croce, Vicky Kwan Wong, Mark G Lebwohl. (2004) Efalizumab in the treatment of psoriasis. Therapy 1:2, 197-202
CrossRef300
Maryann Mikhail, Noah S Scheinfeld. (2004) Therapy treatment options for psoriasis: topical and systemic. Therapy 1:2, 319-330
CrossRef301
C. Costa, N. K. Bell, T. J. Stabel, W. L. Fodor. (2004) Use of porcine tumor necrosis factor receptor 1-Ig fusion protein to prolong xenograft survival. Xenotransplantation 11:6, 491-502
CrossRef302
Alice B. Gottlieb. (2004) Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatologic Therapy 17:5, 401-408
CrossRef303
Lyn Guenther, Richard G. Langley, Neil H. Shear, Robert Bissonnette, Vincent Ho, Charles Lynde, Eileen Murray, Kim Papp, Yves Poulin, Catherine Zip. (2004) Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. Journal of Cutaneous Medicine and Surgery 8:5, 321-337
CrossRef304
Steven R Feldman, Daniel J Pearce. (2004) Management and costs of severe psoriasis: the role of new biologics. Expert Review of Pharmacoeconomics & Outcomes Research 4:5, 573-579
CrossRef305
Andrew Y. Finlay, Jean-Paul Ortonne. (2004) Patient Satisfaction with Psoriasis Therapies: An Update and Introduction to Biologic Therapy. Journal of Cutaneous Medicine and Surgery 8:5, 310-320
CrossRef306
Kim A Papp. (2004) Etanercept in psoriasis. Expert Opinion on Pharmacotherapy 5:10, 2139-2146
CrossRef307
Debra Lewkowicz, Alice B. Gottlieb. (2004) Pediatric psoriasis and psoriatic arthritis. Dermatologic Therapy 17:5, 364-375
CrossRef308
Stephen R. Rapp, Steven R. Feldman. (2004) The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?. Dermatologic Therapy 17:5, 376-382
CrossRef309
Vivek Kak, Daniel Havlichek. (2004) Fulminant Cytomegaloviral Pneumonia After Infliximab in a Patient With Crohn Disease. Infectious Diseases in Clinical Practice 12:5, 311-313
CrossRef310
Roy Fleischmann, Richard Stern, Imran Iqbal. (2004) Etanercept – review of efficacy and safety after five years of clinical use. Therapy 1:1, 11-23
CrossRef311
J. N. W. N. Barker. (2004) A review of recent journal highlights. Clinical and Experimental Dermatology 29:5, 579-581
CrossRef312
Daniel N. Sauder, Adam J. Mamelak. (2004) Understanding the New Clinical Landscape for Psoriasis: A Comparative Review of Biologics. Journal of Cutaneous Medicine and Surgery 8:4, 205-212
CrossRef313
W. Sterry, J. Barker, W.-H. Boehncke, J.D. Bos, S. Chimenti, E. Christophers, M. De La Brassinne, C. Ferrandiz, C. Griffiths, A. Katsambas, K. Kragballe, C. Lynde, A. Menter, J.-P. Ortonne, K. Papp, J. Prinz, B. Rzany, J. Ronnevig, J.-H. Saurat, M. Stahle, F.M. Stengel, P. Van De Kerkhof, J. Voorhees. (2004) Biological therapies in the systemic management of psoriasis: International Consensus Conference. British Journal of Dermatology 151:s69, 3-17
CrossRef314
David Kane, Oliver FitzGerald. (2004) Tumor necrosis factor-α in psoriasis and psoriatic arthritis: A clinical, genetic, and histopathologic perspective. Current Rheumatology Reports 6:4, 292-298
CrossRef315
T. Kormeili, N.J. Lowe, P.S. Yamauchi. (2004) Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. British Journal of Dermatology 151:1, 3-15
CrossRef316
Philip J Mease. (2004) Recent advances in the management of psoriatic arthritis. Current Opinion in Rheumatology 16:4, 366-370
CrossRef317
Wendy Myers, Mobolaji Opeola, Alice B. Gottlieb. (2004) Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis. Current Rheumatology Reports 6:4, 306-313
CrossRef318
Edward Tobinick, Susan Davoodifar. (2004) Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Current Medical Research and Opinion 20:7, 1075-1085
CrossRef319
Francesca Chamian, James G Krueger. (2004) Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Current Opinion in Rheumatology 16:4, 331-337
CrossRef320
Brian J. Nickoloff, Frank O. Nestle. (2004) Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. Journal of Clinical Investigation 113:12, 1664-1675
CrossRef321
Noriyuki Kamei, Tomohiro Tanaka, Kentaro Kawai, Kyosei Miyawaki, Akihiko Okuyama, Yoshiko Murakami, Yoshio Arakawa, Makoto Haino, Tatsuhiro Harada, Masanao Shimano. (2004) Reverse hydroxamate-based selective TACE inhibitors. Bioorganic & Medicinal Chemistry Letters 14:11, 2897-2900
CrossRef322
Wook Lew, Anne M. Bowcock, James G. Krueger. (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and ‘Type 1’ inflammatory gene expression. Trends in Immunology 25:6, 295-305
CrossRef323
Jane Barry, Brian Kirby. (2004) Novel biologic therapies for psoriasis. Expert Opinion on Biological Therapy 4:6, 975-987
CrossRef324
J. Geerling. (2004) Behandeling van plaquepsoriasis met subcutaan toegediend etanercept. Medisch-Farmaceutische Mededelingen 42:5, 130-130
CrossRef325
Sheila A Doggrell. (2004) Efalizumab for psoriasis?. Expert Opinion on Investigational Drugs 13:5, 551-554
CrossRef326
Shikha Nanda, Joan M Bathon. (2004) Etanercept: a clinical review of current and emerging indications. Expert Opinion on Pharmacotherapy 5:5, 1175-1186
CrossRef327
Arndt J. G. Schottelius, Lyle L. Moldawer, Charles A. Dinarello, Khusru Asadullah, Wolfram Sterry, Carl K. Edwards. (2004) Biology of tumor necrosis factor-alpha- implications for psoriasis. Experimental Dermatology 13:4, 193-222
CrossRef328
Makoto INAOKI. (2004) Japanese Journal of Clinical Immunology 27:2, 77-86
CrossRef329
Kupper, Thomas S., . (2003) Immunologic Targets in Psoriasis. New England Journal of Medicine 349:21, 1987-1990
Full Text
